DSGN designtx.com Net Financial Result

DSGN (Design Therapeutics Inc) - company brandmark

Design Therapeutics (DSGN) creates unique small-molecule systems for gene regulation, which eliminates price competition. Market price action reflects profit at the level of -0.07. The business relies on patents in the field of DNA chemical binding, while the high cost of clinical trials and scientific complexity create a significant barrier to entry for new players in this sector.

DSGN Design Pharma Net Profit (07/04/2022 - 10/30/2026)

Comprehensive metric breakdowns and analytics for Design Therapeutics, Inc. (DSGN)

- stock value and consensus price forecast:
Market Price Design Corp|DSGN - Price Target Chart
- market capitalization data:
Market Capitalization Design Corp|DSGN - Enterprise Value
- shareholders' equity book value data:
Net Assets per Share Design Therapeutics|DSGN - Book Capitalization|Market Value to Equity Ratio designtx.com|DSGN - Aggregate Company Assets
- debt burden and liquidity indicators:
Debt to Equity Ratio Design Therapeutics|DSGN - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Design Therapeutics Inc|DSGN - Company Total Debt|Debt to Book Capital Design Corp|DSGN - Company Long-Term Debts|Company Short-Term Loans and Borrowings Design Therapeutics|Immediate Liquidity designtx.com
- earnings and multiples data:
DSGN - Company Net Income
Summary company analysis:Design Corp - DSGN
Brand item of Design Therapeutics Inc

As a portfolio manager, I view this indicator as a marker of operational efficiency. The metric measures the final cash balance after deducting all operating and financial expenses, reflecting the business's sensitivity to the cost of borrowed capital. By analyzing the company's financial result, an investor determines the asset's fundamental stability threshold. For Design Therapeutics (DSGN), this figure demonstrates the cost of small molecule development. Diversification of therapeutic programs allows the company to smooth earnings volatility in the event of failures in individual clinical trials.

Direct competitors

Company Net Income Tempus AI (TEM)|Company Net Income Qiagen N.V.|ionispharma.com (IONS) - Net Financial Result|Net Profit RGEN|Net Financial Result Avidity Biosciences Inc|Net Profit CRSP (CRISPR Therapeutics Corp)|Annual Net Income GeneDx Corp|RARE - Company Net Income|BEAM (beamtx.com) - Company Profit|SRPT (Sarepta) - Net Income|Twist Bioscience Inc - Final Profit|Net Income TXG|NTLA (Intellia Corp) - Profit After Payment of Taxes|Net Profit STOK|BLFS (biolifesolutions.com) - Final Profit|Net Profit WVE (Wave Life Sciences Ltd.)|Maze Therapeutics, Inc. (MAZE) - Company Net Income|SION - Company Net Income|Final Profit PRME (Prime Medicine Bio)|TSHA: Net Profit|uniqure.com (QURE) - Net Profit|Company Net Income MeiraGTx|REGENXBIO Inc - Profit After Tax|Net Profit SLDB|OCGN - Company Net Income|Pacific Biosciences - Net Income|Net Profit benitec.com BNTC|RCKT: Net Income|4DMT - Profit After Payment of Taxes|LXEO: Net Profit|KRRO - Net Financial Result|EDIT (Editas Medicine, Inc.) - Net Profit|Net Income silence-therapeutics.com (SLN)|Company Net Income ProQR Therapeutics N.V. (PRQR)|Net Financial Result codexis.com|Net Profit SGMO (Sangamo)|NAUT: Company Profit|MGX - Company Net Income|Net Financial Result Precision BioSciences Inc. DTIL|GBIO: Net Profit|Annual Net Income Boundless Bio Inc. BOLD|Company Net Income Exicure Inc.|Company Profit IMNN (Celsion Corporation)|Net Profit PHIO|mustangbio.com - Company Profit|Company Net Income TransCode Therapeutics, Inc. RNAZ|BNGO: Company Profit|Applied DNA - Net Profit|BLUE - Net Profit|IPA: Net Profit|Company Profit OMGA|OMIC (Singular Genomics) - Net Profit|Company Net Income Regulus Therapeutics, Inc. RGLS|Company Net Income Syros (SYRS)|Net Financial Result Telesis Bio, Inc|Net Profit TCON (TRACON Pharmaceuticals)|Net Financial Result unitybiotechnology.com (UBX)